Souvick Roy
Prakriti Sen
Madhabananda Kar
Birendranath Banerjee- 1Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States
- 2Department of Surgical Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
- 3All India Institute of Medical Sciences, Darbhanga, Bihar, India
- 4inDNA Centre for Research and Innovation in Molecular Diagnostics, inDNA Life Sciences Private Limited, Bhubaneswar, Odisha, India
- 5JBS Haldane Centre of Molecular Medicine, Silicon University, Bhubaneswar, Odisha, India
Editorial on the Research Topic
Overcoming therapeutic resistance in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent cancers worldwide and comprises at least two forms with distinct etiologies: human papillomavirus (HPV) positive and HPV -negative (1). The majority of HNSCCs primarily originate from the squamous cells lining the tissues of the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses and salivary glands (1, 2). The HNSCCs of the oral cavity are primarily associated with tobacco (smoked or chewed), excessive alcohol consumption and areca nut (betel quid). However, HNSCCs originating in the oropharynx and hypopharynx have been attributed to HPV infection, primarily HPV-16 (1, 2). The standard-of-care for treating head and neck squamous cell carcinoma (HNSCC) involves surgical resection of the primary tumor, followed by adjuvant radiotherapy, platinum-based chemotherapy (cisplatin or carboplatin), targeted therapy with cetuximab, or a combination of these treatment modalities (1–4). In 2016, FDA approved immune check-point inhibitor nivolumab and pembrolizumab for treatment of cisplatin-refractory recurrent or metastatic HNSCC patients whereas for patients who present with unresectable or metastatic disease, pembrolizumab is approved as first-line therapy (5–7). Despite recent advancements, acquired resistance to these treatment modalities remains a major challenge in the treatment of HNSCC (8–10). Patients with recurrent or metastatic disease have limited treatment options and poor 5-year survival rates (9). Therefore, there is an unmet and urgent need to identify molecular biomarkers associated with therapeutic resistance and to elucidate their potential molecular mechanisms. The Research Topic “Overcoming Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma” aims to identify molecular biomarkers and their underlying molecular mechanisms in promoting therapeutic resistance in HNSCC. In addition, this Research Topic also focuses on the development of novel therapeutic strategies and their clinical application in HNSCC patients to overcome therapeutic resistance.
It is well known that HPV positive HNSCC patients typically have better outcomes compared to HPV negative HNSCC patients, partly due to their intrinsic sensitivity to radiation (10–12). The small-molecule kinase inhibitors (smKIs) targeting DNA double-strand breaks and single-strand breaks repair proteins, namely, Ataxia telangiectasia mutated (ATM) or Ataxia telangiectasia mutated and Rad3-related (ATR) kinases, have emerged as an attractive treatment option for the treatment of HNSCC (13–15). In this Research Topic, Meidenbauer et al., explored the impact of combining ATM or ATR inhibitors with hypofractionated radiotherapy (RT) in influencing the immunogenicity of Head and neck squamous cell carcinoma cells. The authors observed that combined treatment of ATM or ATR inhibitor with hypofractionated radiotherapy promoted increased cell death compared to individual treatment with ATM or ATR inhibitors irrespective of HPV status. Furthermore, RT+ ATRi treatment led to upregulation of the immune-stimulatory phenotype to promote anti-tumor immune response. The authors showed a differential expression pattern of pro-inflammatory cytokines between RT+ ATRi and RT+ ATMi treatment in HNSCC cells where RT+ATRi promoted increased expression of pro-inflammatory cytokines such as IL-6, IL-8, TNF-α etc. In contrast, RT+ATMi promoted an immunosuppressive phenotype and led to downregulation of the RIG-I signaling pathway, a cytoplasmic sensing pathway of nucleic acids (16) and upregulation of EDIL3, a known anti-inflammatory factor and immune modulator triggering ‘immune execution’ (17, 18). Although the strategy may be attractive with a scope of lower radiation dosage but further investigation is required to determine the efficacy of combined treatment of ATM or ATR inhibitors with RT in clinical settings.
In this Research Topic, Li et al. presented a case of a 78-year-old man diagnosed with human papillomavirus (HPV+) and programmed death ligand 1 (PD-L1+) tonsillar squamous cell carcinoma (TSCC). TSCC represents 15%-20% of oropharyngeal squamous cell carcinoma (OPSCC) cases and the majority of them are HPV+ (19). The multimodal treatment strategies such as surgery, chemotherapy, radiation and immunotherapy showed favorable outcomes in TSCC patients as compared to single modality treatment (20). In this case report, the patient was treated with intravenous administration of Camrelizumab, a PD-1 inhibitor and gemcitabine (GEM), a chemotherapeutic drug. After 8 cycles of treatment the patient exhibited a partial response (PR) with a moderate increase in tumor size whereas lymph node size was decreased. Subsequently, concurrent treatment with radiotherapy and intravenous nab-paclitaxel led to a complete response with no evidence of recurrence or metastasis after a 12-month follow-up. This study provides evidence that Camrelizumab plus GEM followed by concurrent chemoradiotherapy may be a promising therapeutic strategy for HPV-positive and PD-L1-positive TSCC patients.
In another interesting case report, Otsuka et al. presented the case of a 65-year-old man with a history of smoking who was diagnosed with HNSCC of occult primary origin classified as T0N3bM0, stage IVB with programmed cell death-ligand 1 expression. Immune -related adverse events (irAEs) including cytokine release syndrome (CRS) rarely develop after nivolumab treatment but can be severe and lead to multi-organ failure (21, 22). In this study, the patient experienced repeated recurrence of Immune checkpoint inhibitor (ICI) induced CRS. The patient presented with high fever and hypotension, along with an elevated C-reactive protein level, suggesting the possibility of septic shock. However, all bacterial cultures performed from sputum, urine, and blood were negative. The diagnosis of nivolumab-induced CRS was confirmed based on elevated serum levels of ferritin and IL-6. The patient responded well to high-dose steroids such as methylprednisolone. However, CRS recurred during steroid tapering and coincided with an increased tumor burden. Nevertheless, it was successfully managed with an increased dose of methylprednisolone. The patient’s general health condition was poor and eight months post-discontinuation of nivolumab, the patient died due to cancer progression. This case report suggests that early detection and treatment with steroids are essential in the management of CRS.
Locally advanced hypopharyngeal squamous cell carcinoma (LA HPSCC) is one of the most malignant tumors of the head and neck, with a high recurrence rate and poor prognosis (23–26). In this retrospective, single-arm, single center clinical trial led by Gao et al. the authors compared the clinical efficacy and safety between PD-1 inhibitors, pembrolizumab, plus TP regimen (paclitaxel liposome + nedaplatin) and targeted therapy of nimotuzumab, a monoclonal antibody against EGFR plus TP regimen among LA HPSCC patients in the neoadjuvant setting. Post neoadjuvant treatment, the response was assessed based on RECIST criteria. It was observed that in both the treatment groups, the objective response rate (ORR) and disease control rate (DCR) were similar with no significant differences, but the pathological complete response (pCR) rate was much higher in Group A than in Group B. Furthermore, the rate of primary tumor downstaging and 1-year overall survival were much higher in Group A LA HPSCC patients. In addition, the larynx function preservation rate was significantly higher in Group A patients and both treatment strategies did not exhibit a significant difference in the incidence of grade 3-4 treatment-related adverse events (TRAEs). These results suggest that PD-1 inhibitors combined with chemotherapy in the neoadjuvant setting showed better short-term efficacy compared to targeted therapy and exhibit a trend toward improved long-term survival in LA HPSCC patients.
In another interesting pilot clinical trial conducted by Yoon et al. the authors explored the efficacy and safety of the topical toll-like receptor-7 (TLR-7) agonist, imiquimod, in the neoadjuvant setting in patients with early-stage oral squamous cell carcinoma (OSCC). Previous reports suggest that Imiquimod exerts an anti-tumor activity by stimulating innate and adaptive immunity and promoting tumor cell apoptosis (25, 27, 28). In this single-arm, open label pilot study, imiquimod 5% cream was self-administered to early-stage OSCC patients (clinical T1 and T2 without nodal involvement) for 28 days followed by surgical resection of the tumor. It was observed that 60% of early-stage OSCC patients experienced a >50% reduction in tumor cell count following imiquimod treatment. It was also observed that 60% of patients had an immune-related major pathologic response (irMPR) with two patients reporting a complete pathologic response, and 40% of patients had a partial response (PR) with the percent residual viable tumor ranging from 25% to 65%. It was observed that helper and cytotoxic T-cells significantly contributed to the reduction in the tumor. The treatment was well tolerated at the application site, and no patients experienced grade 4 life-threatening events. The median follow-up time was 17 months for 14 patients, and 13 (93%) out of 14 patients had a 1-year recurrence-free survival after neoadjuvant imiquimod therapy. This study highlights that neoadjuvant imiquimod immunotherapy can be a safe and promising treatment option for early-stage OSCC.
This Research Topic also includes a review article summarizing the clinical application of exosomal circular RNA in squamous cell carcinoma. CircRNAs are single-stranded non-coding-RNAs that regulate gene expression, and are easily detectable in blood, rendering them ideal candidates as non-invasive biomarkers (29, 30). Tumor-derived exosomal cargo containing CircRNAs offers an attractive platform for the development of cancer-specific diagnostic and prognostic biomarkers and is likely to provide mechanistic insights for the identification of therapeutic targets (31, 32). In this review article by Wang et al. the authors summarized the biological functions of exosomal circRNAs, their expression pattern and their role in promoting metastasis and therapy resistance in squamous cell carcinoma (SCC). In addition, the authors also reviewed the existing literature highlighting the exosomal circRNAs as diagnostic and prognostic biomarkers along with their potential as a therapeutic target in SCC.
In summary this Research Topic represents an important and diverse contribution in the field of head and neck cancer with novel and unique treatment strategies to overcome therapy resistance in HNSCC. Finally, this Research Topic includes a review article summarizing the clinical significance of exosomal circular RNA in the pathogenesis of SCC and its utility for clinical applications. The field of HNSCC research and the quest to find novel therapeutic strategies for effectively overcoming resistance and minimizing the chance of recurrence to increase disease-free survival are growing rapidly. We are hopeful that the advent of new biomarkers along with the clinical efficacy of new molecules will lead to a decrease in the disease burden in the coming decade.
Author contributions
SR: Writing – original draft, Writing – review & editing. PS: Writing – original draft. MK: Writing – review & editing. BB: Writing – review & editing.
Conflict of interest
Author BB was employed by the company inDNA Life Sciences Private Limited.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Barsouk A, Aluru JS, Rawla P, Saginala K, and Barsouk A. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med Sci (Basel). (2023) 11:42. doi: 10.3390/medsci11020042
2. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, and Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. (2020) 6:92. doi: 10.1038/s41572-020-00224-3
3. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. (2006) 354:567–78. doi: 10.1056/NEJMoa053422
4. Goel B, Tiwari AK, Pandey RK, Singh AP, Kumar S, Sinha A, et al. Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-an update on clinical trials. Transl Oncol. (2022) 21:101426. doi: 10.1016/j.tranon.2022.101426
5. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (Keynote-048): A randomised, open-label, phase 3 study. Lancet. (2019) 394:1915–28. doi: 10.1016/S0140-6736(19)32591-7
6. Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. (2016) 375:1856–67. doi: 10.1056/NEJMoa1602252
7. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (Keynote-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. (2016) 17:956–65. doi: 10.1016/S1470-2045(16)30066-3
8. Denaro N, Merlano MC, and Russi EG. Follow-up in head and neck cancer: do more does it mean do better? A systematic review and our proposal based on our experience. Clin Exp Otorhinolaryngol. (2016) 9:287–97. doi: 10.21053/ceo.2015.00976
9. Gormley M, Creaney G, Schache A, Ingarfield K, and Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. (2022) 233:780–6. doi: 10.1038/s41415-022-5166-x
10. Guo T, Kang SY, and Cohen EEW. Current perspectives on recurrent hpv-mediated oropharyngeal cancer. Front Oncol. (2022) 12:966899. doi: 10.3389/fonc.2022.966899
11. Sun Y, Wang Z, Qiu S, and Wang R. Therapeutic strategies of different hpv status in head and neck squamous cell carcinoma. Int J Biol Sci. (2021) 17:1104–18. doi: 10.7150/ijbs.58077
12. Zhou C and Parsons JL. The radiobiology of hpv-positive and hpv-negative head and neck squamous cell carcinoma. Expert Rev Mol Med. (2020) 22:e3. doi: 10.1017/erm.2020.4
13. Karukonda P, Odhiambo D, and Mowery YM. Pharmacologic inhibition of ataxia telangiectasia and rad3-related (Atr) in the treatment of head and neck squamous cell carcinoma. Mol Carcinog. (2022) 61:225–38. doi: 10.1002/mc.23384
14. Sankunny M, Parikh RA, Lewis DW, Gooding WE, Saunders WS, and Gollin SM. Targeted inhibition of atr or chek1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss. Genes Chromosomes Cancer. (2014) 53:129–43. doi: 10.1002/gcc.22125
15. Weber AM and Ryan AJ. Atm and atr as therapeutic targets in cancer. Pharmacol Ther. (2015) 149:124–38. doi: 10.1016/j.pharmthera.2014.12.001
16. Rehwinkel J and Gack MU. Rig-I-like receptors: their regulation and roles in rna sensing. Nat Rev Immunol. (2020) 20:537–51. doi: 10.1038/s41577-020-0288-3
17. Gasca J, Flores ML, Jiménez-Guerrero R, Sáez ME, Barragán I, Ruíz-Borrego M, et al. Edil3 promotes epithelial–mesenchymal transition and paclitaxel resistance through its interaction with integrin Avβ3 in cancer cells. Cell Death Discov. (2020) 6:86. doi: 10.1038/s41420-020-00322-x
18. Tabasum S, Thapa D, Giobbie-Hurder A, Weirather JL, Campisi M, Schol PJ, et al. Edil3 as an angiogenic target of immune exclusion following checkpoint blockade. Cancer Immunol Res. (2023) 11:1493–507. doi: 10.1158/2326-6066.Cir-23-0171
19. Wang J, Li X, Niu D, Huang J, Ye E, Zhao Y, et al. Mortality patterns of patients with tonsillar squamous cell carcinoma: A population-based study. Front Endocrinol (Lausanne). (2023) 14:1158593. doi: 10.3389/fendo.2023.1158593
20. Roden DF, Schreiber D, and Givi B. Multimodality treatment of early-stage tonsil cancer. Otolaryngology–Head Neck Surg. (2017) 157:62–8. doi: 10.1177/0194599817696290
21. Ntwali F, Gilliaux Q, and Honoré PM. Nivolumab-induced cytokine release syndrome: A case report and literature review. Am J Case Rep. (2024) 25:e941835. doi: 10.12659/ajcr.941835
22. Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst A-M, Chan YH, et al. Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: A case series of 25 patients and review of the literature. Front Immunol. (2022) 13:807050. doi: 10.3389/fimmu.2022.807050
23. Newman JR, Connolly TM, Illing EA, Kilgore ML, Locher JL, and Carroll WR. Survival trends in hypopharyngeal cancer: A population-based review. Laryngoscope. (2015) 125:624–9. doi: 10.1002/lary.24915
24. Iwae S, Fujii M, Hayashi R, Hasegawa Y, Fujii T, Okami K, et al. Matched-pair analysis of patients with advanced hypopharyngeal cancer: surgery versus concomitant chemoradiotherapy. Int J Clin Oncol. (2017) 22:1001–8. doi: 10.1007/s10147-017-1151-9
25. Lim SH, Lee SJ, Ahn M-J, Park K, and Sun J-M. Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy. Japanese J Clin Oncol. (2015) 46:40–5. doi: 10.1093/jjco/hyv163
26. Huang T-Q, Wang R, Fang J-G, He S-Z, Zhong Q, Hou L-Z, et al. Induction chemotherapy for the individualised treatment of hypopharyngeal carcinoma with cervical oesophageal invasion: A retrospective cohort study. World J Surg Oncol. (2020) 18:330. doi: 10.1186/s12957-020-02095-0
27. Xiong Z and Ohlfest JR. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. J Immunotherapy. (2011) 34:264–9. doi: 10.1097/CJI.0b013e318209eed4
28. Sohn K-C, Li ZJ, Choi D-K, Zhang T, Lim JW, Chang I-K, et al. Imiquimod induces apoptosis of squamous cell carcinoma (Scc) cells via regulation of A20. PloS One. (2014) 9:e95337. doi: 10.1371/journal.pone.0095337
29. Li J, Sun D, Pu W, Wang J, and Peng Y. Circular rnas in cancer: biogenesis, function, and clinical significance. Trends Cancer. (2020) 6:319–36. doi: 10.1016/j.trecan.2020.01.012
30. Roy S, Kanda M, Nomura S, Zhu Z, Toiyama Y, Taketomi A, et al. Diagnostic efficacy of circular rnas as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer. Mol Cancer. (2022) 21:42. doi: 10.1186/s12943-022-01527-7
31. Wang M, Yu F, Li P, and Wang K. Emerging function and clinical significance of exosomal circrnas in cancer. Mol Ther Nucleic Acids. (2020) 21:367–83. doi: 10.1016/j.omtn.2020.06.008
Keywords: head and neck squamous cell carcinoma, therapy resistance, molecular biomarker, cancer stem cells, novel therapeutics
Citation: Roy S, Sen P, Kar M and Banerjee B (2025) Editorial: Overcoming therapeutic resistance in head and neck squamous cell carcinoma. Front. Oncol. 15:1611819. doi: 10.3389/fonc.2025.1611819
Received: 14 April 2025; Accepted: 08 May 2025;
Published: 05 June 2025.
Edited and Reviewed by:
Tao Liu, University of New South Wales, AustraliaCopyright © 2025 Roy, Sen, Kar and Banerjee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Souvick Roy, czZyb3lAaGVhbHRoLnVjc2QuZWR1; Birendranath Banerjee, YmlyZW4uYmFuZXJqZWVAc2lsaWNvbi5hYy5pbg==